Balaji Amines Limited — Investor Meet, 18-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Balaji Amines reported Q2 FY '26 consolidated revenue of INR 341 crores, EBITDA of INR 67 crores (19% margin), and PAT of INR 37 crores. For H1 FY '26, revenue was INR 715 crores and PAT was INR 74 crores.

Management anticipates a gradual improvement and 8-10% volume growth in H2 FY '26, with new capacities for DME and N-Methyl Morpholine expected to commission in FY '25-26, and Acetonitrile expansion in FY '26-27. Balaji Specialty Chemicals' INR 750 crore expansion is progressing, with Unit 1 brownfield for EDA-based products and Unit 2 greenfield projects commissioning by September and December 2026, respectively. The company maintains zero debt, funding all projects internally. Long-term outlook remains positive, driven by import substitution and product diversification.